Categories Consumer, Earnings

Earnings Summary: TJX Companies reports higher sales and profit for Q3 2025

Apparel retailer The TJX Companies, Inc. (NYSE: TJX) on Wednesday reported an increase in net sales and profit for the third quarter of fiscal 2025.

  • Third-quarter comparable store sales increased by 3%, entirely driven by an increase in customer transactions
  • Net sales for the quarter were $14.1 billion, an increase of 6% from the third quarter of fiscal 2024
  • Q3 net income increased to $1.3 billion or $1.14 per share from $1.19 billion or $1.03 in the year-ago quarter
  • The pretax profit margin came in at 12.3% in Q3, up 0.3 percentage points versus last year and above the company’s guidance
  • During the quarter, TJX returned $997 million to shareholders through share repurchases and dividends
  • Gross profit margin for the quarter was 31.6%, up 0.5 percentage points from last year, reflecting higher merchandise margin
  • For the fourth quarter, the company continues to expect consolidated comparable store sales to be up 2%-3%
  • For fiscal 2025, the management continues to expect consolidated comparable store sales to be up 3%

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top